ECSP088310A - Composición farmacéutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpética - Google Patents

Composición farmacéutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpética

Info

Publication number
ECSP088310A
ECSP088310A EC2008008310A ECSP088310A ECSP088310A EC SP088310 A ECSP088310 A EC SP088310A EC 2008008310 A EC2008008310 A EC 2008008310A EC SP088310 A ECSP088310 A EC SP088310A EC SP088310 A ECSP088310 A EC SP088310A
Authority
EC
Ecuador
Prior art keywords
treatment
brivudine
herpetetic
cheratitis
pharmaceutical composition
Prior art date
Application number
EC2008008310A
Other languages
English (en)
Inventor
Marc Wihsmann
Reinhard Schmitz
Original Assignee
Berlin Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berlin Chemie Ag filed Critical Berlin Chemie Ag
Publication of ECSP088310A publication Critical patent/ECSP088310A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones farmacéuticas que contienen el antiviral brivudina, útiles para el tratamiento de condiciones inflamatorias oculares, particularmente la queratitis estromal inducida por el Virus del Herpes Simple Tipo 1 (HSV-1) o por el Virus de la Varicela-Zóster (VZV). Las composiciones permiten la fotoprotección del antiviral con excelente tolerancia y administración prolongada de la brivudina.
EC2008008310A 2005-09-29 2008-03-25 Composición farmacéutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpética ECSP088310A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005046769A DE102005046769A1 (de) 2005-09-29 2005-09-29 Lichtstabile, brivudinhaltige pharmazeutische Formulierung zur Behandlung von Augenherpes (Herpes Ophthalmicus)
PCT/EP2006/009383 WO2007039201A2 (en) 2005-09-29 2006-09-27 Photostable pharmaceutical composition containing brivudine for the treatment of herpetic keratitis

Publications (1)

Publication Number Publication Date
ECSP088310A true ECSP088310A (es) 2008-05-30

Family

ID=37561306

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008310A ECSP088310A (es) 2005-09-29 2008-03-25 Composición farmacéutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpética

Country Status (33)

Country Link
US (1) US20080249061A1 (es)
EP (1) EP1940353B1 (es)
JP (1) JP2009509993A (es)
KR (1) KR20080053319A (es)
CN (1) CN101272765A (es)
AP (1) AP2008004394A0 (es)
AR (1) AR056551A1 (es)
AT (1) ATE489076T1 (es)
AU (1) AU2006299115A1 (es)
BR (1) BRPI0616449A2 (es)
CA (1) CA2624111A1 (es)
CR (1) CR9839A (es)
CY (1) CY1111059T1 (es)
DE (2) DE102005046769A1 (es)
DK (1) DK1940353T3 (es)
EA (1) EA012975B1 (es)
EC (1) ECSP088310A (es)
ES (1) ES2356774T3 (es)
HN (1) HN2008000497A (es)
HR (1) HRP20110085T1 (es)
IL (1) IL190466A0 (es)
MA (1) MA29887B1 (es)
NO (1) NO20081488L (es)
PE (1) PE20070767A1 (es)
PL (1) PL1940353T3 (es)
PT (1) PT1940353E (es)
RS (1) RS51615B (es)
SI (1) SI1940353T1 (es)
TN (1) TNSN08094A1 (es)
TW (1) TW200744664A (es)
UA (1) UA90911C2 (es)
WO (1) WO2007039201A2 (es)
ZA (1) ZA200802729B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009006130A2 (en) * 2007-06-28 2009-01-08 Bausch & Lomb Incorporated Salt free hyaluronate ophthalmic solution
WO2009100367A2 (en) * 2008-02-06 2009-08-13 Adherex Technologies Inc. Compositions comprising topical dpd inhibitors and methods of using same in the treatment of hand-foot syndrome
DE102009003942A1 (de) * 2009-01-07 2010-07-08 D2O Biosience Group Ltd., Hamilton Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges
RS58731B1 (sr) 2014-01-22 2019-06-28 Visufarma B V Kompozicija koja sadrži jota-karagenan protiv virusnog konjuktivitisa
AU2017261303B9 (en) * 2016-05-06 2021-09-23 Sacsh, Inc. Ophthalmic compositions
CN113712928A (zh) * 2021-09-29 2021-11-30 重庆市力扬医药开发有限公司 经口腔粘膜吸收的溴夫定药物
EP4623919A1 (en) 2024-03-28 2025-10-01 Marinomed Biotech AG Composition comprising iota-carrageenan for the treatment of dry eyes, non-viral conjunctivitis and allergic ocular conditions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY136633A (en) * 2001-01-17 2008-11-28 Berlin Chemie Ag Stabilized brivudine topical formulations
DE10162593A1 (de) * 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen

Also Published As

Publication number Publication date
AU2006299115A1 (en) 2007-04-12
BRPI0616449A2 (pt) 2011-06-21
PL1940353T3 (pl) 2011-05-31
PE20070767A1 (es) 2007-08-13
TW200744664A (en) 2007-12-16
TNSN08094A1 (en) 2009-07-14
CY1111059T1 (el) 2015-06-11
WO2007039201A3 (en) 2007-10-04
MA29887B1 (fr) 2008-10-03
SI1940353T1 (sl) 2011-03-31
JP2009509993A (ja) 2009-03-12
CR9839A (es) 2008-10-31
HRP20110085T1 (hr) 2011-03-31
KR20080053319A (ko) 2008-06-12
UA90911C2 (ru) 2010-06-10
DK1940353T3 (da) 2011-01-24
EP1940353A2 (en) 2008-07-09
ATE489076T1 (de) 2010-12-15
ES2356774T3 (es) 2011-04-13
EA012975B1 (ru) 2010-02-26
CN101272765A (zh) 2008-09-24
PT1940353E (pt) 2011-02-25
AU2006299115A2 (en) 2008-05-29
ZA200802729B (en) 2009-09-30
US20080249061A1 (en) 2008-10-09
AR056551A1 (es) 2007-10-10
AP2008004394A0 (en) 2008-04-30
EA200800646A1 (ru) 2008-10-30
WO2007039201A2 (en) 2007-04-12
DE602006018505D1 (de) 2011-01-05
HN2008000497A (es) 2010-09-10
NO20081488L (no) 2008-03-26
CA2624111A1 (en) 2007-04-12
RS51615B (sr) 2011-08-31
IL190466A0 (en) 2008-11-03
DE102005046769A1 (de) 2007-04-05
EP1940353B1 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
ECSP088310A (es) Composición farmacéutica fotoestable que contiene brivudina para el tratamiento de la queratitis herpética
AR052771A1 (es) Pirimidinas biciclicas inhibidoras del vhc
AR056850A1 (es) MÉTODOS Y KITS PARA DOSIFICAR NUCLEoSIDOS ANTIVIRALES BETA-D-2',3'-DIDEHIDRO-2',3' DIDEOXI-5-FLUOROCITIDINA
ECSP055801A (es) Compuestos benzofuránicos, composiciones y métodos para el tratamiento y profilaxis de infecciones virales de hepatitis c y enfermedades asociadas
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
UY28582A1 (es) Métodos para preparar derivados 7-(b (beta)-d-ribofuranosilo sustituido en 2´)-4(nr2r3)-5-(etin-1-ilo sustituido) -pirrol(2,3-d) pirimidina
PA8588501A1 (es) Derivados antivirales de nucleósidos
ECSP099462A (es) Aril fosforamidatos de nucleosido y su uso como agentes antivirales para el tratamiento del virus de la hepatitis c
CL2008000959A1 (es) Compuestos derivados de 1,2,4-tiadiazina o 1,4-tiazina; composiciones farmaceuticas que los contienen; y su uso para la prevencion y/o tratamiento de infecciones producidas por el virus de la hepatitis c.
BRPI0414062A (pt) uso de ciclosporinas midificadas para o tratamento de distúrbios por hcv
BR0305426A (pt) Compostos inibidores de ns5b polimerase de hcv, bem como composição farmacêutica compreendendo os mesmos
ECSP099319A (es) Analogos de tiofeno para el tratamiento o prevencion de las infecciones por flavivirus
UY32462A (es) Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644
CL2013002467A1 (es) Composición oftálmica que comprende al menos 0,67% pero no más de 1,0% p/v de olopatadina disuelta en solucion, peg con un peso molecular de 300 a 500, polivinilpirrolidona, hidroxialquil ß-ciclodextrina, hidroxialquil ?-ciclodextrina o su combinación y cloruro de benzalconio; gotario que comprende a la composición oftálmica; y su uso en el tratamiento de la conjuntivitis alérgica ocular.
UY29516A1 (es) Derivados de purina
ECSP10010210A (es) Compuestos nucleósidos antivirales
PA8804701A1 (es) Nucleosidos 2'4'-sustituidos como agentes antivirales
NO20090029L (no) Pyrrolopyrimidiner for farmasoytiske formuleringer
BRPI0411528A (pt) uso de isomalte como prebiótico
ECSP13012560A (es) Análogos de carba-nucleósidos sustituidos con 2'-fluoro para tratamiento antiviral.
PE20170203A1 (es) Derivados de nucleosido sustituidos con 4'-difluorometilo como inhibidores de la replicacion de arn de la influeza
ATE481382T1 (de) Neue substituierte arylsulphonylglycine, ihre herstellung und ihre verwendung als pharmazeutische zusammensetzungen
CU24519B1 (es) Derivados de aminotiazol útiles como agentes antivíricos
ATE534652T1 (de) Phosphono-pent-2-en-1-yl-nukleoside und analoga
CR20110284A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento